Transactions are the driving force behind the life sciences sector, fueling innovation in human health.
Success in life sciences deals requires sophisticated legal skill and a thorough understanding of the realities our clients face every day, from the markets and competitors to the government and the supply chain. Our multidisciplinary team applies deep industry know-how and market insight to provide holistic guidance throughout our clients’ business cycles, from early-stage to going public.
Corporate growth is built on long-term, successful relationships between companies and their investors.
We understand market standards and how to negotiate and structure transactions that build long-term, successful relationships between life sciences companies and their investors.
In addition to venture financings from seed to late-stage, we help borrowers secure innovative and competitive financing arrangements, and are well-versed in the industry-specific nuances of these transactions. We also represent general partners and venture investors in fund formation, domestic and foreign tax planning, and fund investment in portfolio companies.
M&A is the economic engine that drives the life sciences industry.
Our attorneys are highly responsive, multi-disciplined, and creative problem-solvers who have dedicated their careers to helping life sciences clients succeed.
We bring our knowledge of the life sciences industry to guide sellers, purchasers, target companies, special committees, and financial advisors in domestic and cross-border transactions.
Our deal teams are lean, efficient, and well-supported by subject matter experts in critical areas such as intellectual property, FDA regulatory compliance, antitrust, tax, employment and benefits law, finance, environmental, and real estate.
Strategic partnerships are essential to the development and distribution of novel products and technologies.
Novel ideas often emanate from new, entrepreneurial companies that do not have the resources to scale effectively. Licensing and collaboration agreements enable innovators to create the reach they need and to optimize their potential.
We are experienced in facilitating long-term collaborations, joint ventures and strategic alliances, life-of-patent licensing arrangements, and other agreements, such as pre-clinical and clinical sponsored research, CRO, clinical trials, manufacturing and supply agreements; and distribution, and marketing and sales agreements.
We know how to resolve the complexities, issues and potential roadblocks involved with creating successful partnering relationships.
Navigating today's rapidly changing capital markets and regulatory environment can be challenging.
Moving a life sciences company from an idea to a profitable entity and public company requires a focused and well-coordinated strategy that balances growth and risk, provides governance, and complies with regulations and securities laws. We structure, negotiate and document sophisticated equity and debt financing transactions such as IPOs, follow-on public offerings and PIPE transactions. We are experienced in working with foreign and domestic issuers, underwriters, selling and controlling shareholders, and other market participants in capital markets transactions.
We are highly attuned to changing market terms and regulatory requirements. We focus on minimizing regulatory and economic risk while maximizing our clients' potential opportunities.
Regulators' push for more transparency has made compliance increasingly complex.
Life sciences companies continue to face increasingly complex regulatory requirements in areas such as entity background and clinical trial results, while new securities registrants are attracting particular scrutiny.
We help public companies, boards of directors, committees, and management to comply with federal and state securities laws and regulations, stock exchange listing standards, and other governance requirements.
We offer deep experience serving as outside securities counsel to public companies, and have a long track record of handling all aspects of SEC reporting and compliance for companies of all sizes.
Addressing IP, HSR/antitrust, tax and employee benefits issues from the outset optimizes deal outcomes and corporate growth objectives.
Our health sciences team includes attorneys with mastery in all legal areas that are implicated in transactions. They anticipate regulatory hurdles, structure deals that minimize tax impact, protect and monetize business-critical assets, and ensure that key personnel are retained and appropriately rewarded.
Our dedicated health sciences intellectual property team works with clients to protect leading-edge technologies, breakthrough products, market identities, and other core strategic assets.
Antitrust scrutiny of life sciences transactions is intensifying. Our antitrust attorneys have successfully shepherded deals through the HSR clearance process for years, and successfully defend against competition litigation.
We offer state-of-the-art tax services on U.S. and international deals, and our employee benefits and executive compensation attorneys craft solutions that address ERISA, tax, employment and securities laws.
Sponsored Events
07.25.24
ACI 11th Annual Summit for Women Leaders in Life Sciences Law 2024
Speaking Engagements
06.20.24
MassBio General Counsel Roundtable with Troutman Pepper
Firm News
06.13.24
Troutman Pepper Partner Deborah Spranger Selected for Fellows of the American Bar Foundation
Sponsored Events
06.02.24
2024 BIO International BioBreak Networking Reception
Sponsored Events
05.21.24
2024 Philadelphia Alliance for Capital and Technologies (PACT) Enterprise Awards
Sponsored Events
05.09.24
Boston Boost by BioBreak Spring Reception 2024